On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug.On Wednesday, Amgen Inc AMGN stated the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data, saying, “Amgen does not see an association between the administration of MariTide and bone mineral density (BMD) changes. The Phase 1 study results do not suggest any bone safety concerns or change our conviction in the promise of MariT ...